SCHEMBL112688

SCHEMBL112688

CCc1ccc(N)c(Cl)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.38
NOS2 P35228 1/20 0.38
PARP1 P09874 1/20 0.36
CYP3A4 P08684 5/20 0.33
SMN1; SMN2 Q16637 4/20 0.33
ALDH1A1 P00352 4/20 0.33
DHFR P00374 3/20 0.33
TDP1 Q9NUW8 2/20 0.33
CYP1A2 P05177 2/20 0.33
CYP2C9 P11712 2/20 0.33
MEN1 O00255 1/20 0.33
SLC22A1 O15245 1/20 0.33
LMNA P02545 1/20 0.33
TP53 P04637 1/20 0.33
HEXA P06865 1/20 0.33
HEXB P07686 1/20 0.33
HTR1A P08908 1/20 0.33
ADRA2A P08913 1/20 0.33
CYP2D6 P10635 1/20 0.33
HTR2A P28223 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10399548 0.79 NOS3 (0.39) NOS3NOS2PARP1CYP3A4SMN1; SMN2
SCHEMBL21604163 0.77 NOS3 (0.42) NOS3NOS2PARP1CYP3A4SMN1; SMN2
SCHEMBL17987117 0.77 S1PR4 (0.41) CYP3A4SMN1; SMN2ALDH1A1TDP1TSHR
SCHEMBL28350212 0.77 NOS2 (0.43) NOS3NOS2SMN1; SMN2ALDH1A1SLC6A3
SCHEMBL10271989 0.76 PARP1 (0.34) NOS3NOS2PARP1CYP3A4ALDH1A1
SCHEMBL20110642 0.74 ALDH1A1 (0.35) NOS3NOS2PARP1CYP3A4ALDH1A1
SCHEMBL24590757 0.73 MBOAT4 (0.40) PARP1CYP3A4SMN1; SMN2ALDH1A1DHFR
SCHEMBL25542889 0.73 CYP1A2 (0.33) PARP1CYP3A4SMN1; SMN2ALDH1A1DHFR
SCHEMBL29923201 0.72 NOS3 (0.34) NOS3NOS2PARP1CYP3A4SMN1; SMN2
SCHEMBL29847754 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 US disclosed
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 US disclosed
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 US disclosed
EP-2408769-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS Glaxo Group Limited (GB) 2012-01-25 EP disclosed
WO-2010106016-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2010-09-23 WO disclosed
WO-2010106016-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2010-09-23 WO disclosed
US-5086181-A Promoter for animal feeds; animal growth regulators BAYER AKTIENGESELLSCHAFT (DE) 1992-02-04 US disclosed
US-4988694-A Promoters for animal growth regulators for animal feeds BAYER AKTIENGESELLSCHAFT (DE) 1991-01-29 US disclosed
EP-0339345-A2 4-Bromo-6-chloro-5-amino-2-pyridyl-ethanol amines, process for their preparation and their use as performance stimulators BAYER AG (DE) 1989-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS DTYMK, ITK, DCK NOS3 3602/4885NOS2 2977/4885PARP1 866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.